Personalis (NASDAQ:PSNL) Releases Earnings Results, Misses Expectations By $0.06 EPS

Personalis (NASDAQ:PSNL) released its earnings results on Wednesday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.06), FiscalAI reports. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. The company had revenue of $25.60 million for the quarter, compared to the consensus estimate of $21.54 million.

Personalis Stock Performance

Shares of PSNL traded up $0.04 during mid-day trading on Wednesday, reaching $15.79. The company had a trading volume of 2,217,743 shares, compared to its average volume of 2,610,416. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -14.49 and a beta of 2.40. Personalis has a 1-year low of $4.95 and a 1-year high of $18.89. The company’s 50 day simple moving average is $16.26 and its 200 day simple moving average is $11.39.

Analyst Upgrades and Downgrades

PSNL has been the topic of a number of analyst reports. Zacks Research upgraded Personalis from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Morgan Stanley raised their target price on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. UBS Group cut shares of Personalis from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 6th. Needham & Company LLC downgraded Personalis from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Personalis presently has an average rating of “Hold” and a consensus price target of $14.54.

Insider Buying and Selling at Personalis

In other news, CMO Richard Chen sold 3,998 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $64,847.56. Following the completion of the transaction, the chief marketing officer owned 169,882 shares of the company’s stock, valued at approximately $2,755,486.04. This trade represents a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Christopher Hall sold 7,459 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $120,984.98. Following the transaction, the chief executive officer owned 228,527 shares of the company’s stock, valued at $3,706,707.94. This trade represents a 3.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 16,456 shares of company stock valued at $266,916. Insiders own 4.20% of the company’s stock.

Personalis Company Profile

Personalis, Inc is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.

Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal.